Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Urological Cancer Drugs for these regions, from 2012 to 2023 (forecast), covering

China

USA

Europe

Japan

Korea

India

Global Urological Cancer Drugs market competition by top manufacturers/players, with Urological Cancer Drugs sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline

Indevus Pharmaceuticals Inc

Ipsen

Roche Healthcare

Sanofi S.A.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Xofigo (Radium Ra 223 Dichloride)

Jevtana (Cabazitaxel)

Inlyta (Axitinib)

Votrient (Pazopanib Hydrochloride)

Sutent (Sunitinib Malate)

Zytiga (Abiraterone Acetate)

? ? Xtandi (Enzalutamide)

? ? Opdivo (Nivolumab)

? ? Provenge (Sipuleucel-T)

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Urological Cancer Drugs for each application, including

Prostate Cancer

Bladder Cancer

Kidney Cancer

Testicular Cancer

If you have any special requirements, please let us know and we will offer you the report as you want.

Table Of Content

Table of Contents

1 Report Overview
    1.1 Definition and Specification
    1.2 Report Overview
        1.2.1 Manufacturers Overview
        1.2.2 Regions Overview
        1.2.3 Type Overview
        1.2.4 Application Overview
    1.3 Industrial Chain
        1.3.1 Urological Cancer Drugs Overall Industrial Chain
        1.3.2 Upstream
        1.3.3 Downstream
    1.4 Industry Situation
        1.4.1 Industrial Policy
        1.4.2 Product Preference
        1.4.3 Economic/Political Environment
    1.5 SWOT Analysis
2 Market Analysis by Types
    2.1 Overall Market Performance(Volume)
             2.1.1  Xofigo (Radium Ra 223 Dichloride) Market Performance (Volume)
             2.1.2   Jevtana (Cabazitaxel) Market Performance (Volume)
             2.1.3   Inlyta (Axitinib) Market Performance (Volume)
             2.1.4   Votrient (Pazopanib Hydrochloride) Market Performance (Volume)
             2.1.5   Sutent (Sunitinib Malate) Market Performance (Volume)
    2.2 Overall Market Performance(Value)
             2.1.1  Xofigo (Radium Ra 223 Dichloride) Market Performance (Value)
             2.1.2   Jevtana (Cabazitaxel) Market Performance (Value)
             2.1.3   Inlyta (Axitinib) Market Performance (Value)
             2.1.4   Votrient (Pazopanib Hydrochloride) Market Performance (Value)
             2.1.5   Sutent (Sunitinib Malate) Market Performance (Value)
3 Product Application Market
    3.1 Overall Market Performance (Volume)
             3.1.1  Prostate Cancer Market Performance (Volume)
             3.1.2   Bladder Cancer Market Performance (Volume)
             3.1.3   Kidney Cancer Market Performance (Volume)
             3.1.4   Testicular Cancer Market Performance (Volume)
4 Manufacturers Profiles/Analysis
    4.1   Novartis 
        4.1.1   Novartis Profiles 
        4.1.2   Novartis Product Information 
        4.1.3   Novartis Urological Cancer Drugs Business Performance  
        4.1.4   Novartis Urological Cancer Drugs Business Development and Market Status  
    4.2   Pfizer 
        4.2.1   Pfizer Profiles 
        4.2.2   Pfizer Product Information 
        4.2.3   Pfizer Urological Cancer Drugs Business Performance  
        4.2.4   Pfizer Urological Cancer Drugs Business Development and Market Status  
    4.3   Johnson & Johnson 
        4.3.1   Johnson & Johnson Profiles 
        4.3.2   Johnson & Johnson Product Information 
        4.3.3   Johnson & Johnson Urological Cancer Drugs Business Performance  
        4.3.4   Johnson & Johnson Urological Cancer Drugs Business Development and Market Status  
    4.4   AstraZeneca 
        4.4.1   AstraZeneca Profiles 
        4.4.2   AstraZeneca Product Information 
        4.4.3   AstraZeneca Urological Cancer Drugs Business Performance  
        4.4.4   AstraZeneca Urological Cancer Drugs Business Development and Market Status  
    4.5   Astellas 
        4.5.1   Astellas Profiles 
        4.5.2   Astellas Product Information 
        4.5.3   Astellas Urological Cancer Drugs Business Performance  
        4.5.4   Astellas Urological Cancer Drugs Business Development and Market Status  
    4.6   Bristol-Myers Squibb 
        4.6.1   Bristol-Myers Squibb Profiles 
        4.6.2   Bristol-Myers Squibb Product Information 
        4.6.3   Bristol-Myers Squibb Urological Cancer Drugs Business Performance  
        4.6.4   Bristol-Myers Squibb Urological Cancer Drugs Business Development and Market Status  
    4.7   Abbott Laboratories 
        4.7.1   Abbott Laboratories Profiles 
        4.7.2   Abbott Laboratories Product Information 
        4.7.3   Abbott Laboratories Urological Cancer Drugs Business Performance  
        4.7.4   Abbott Laboratories Urological Cancer Drugs Business Development and Market Status  
    4.8   Celgene Corporation 
        4.8.1   Celgene Corporation Profiles 
        4.8.2   Celgene Corporation Product Information 
        4.8.3   Celgene Corporation Urological Cancer Drugs Business Performance  
        4.8.4   Celgene Corporation Urological Cancer Drugs Business Development and Market Status  
    4.9   Dendreon Corporation 
        4.9.1   Dendreon Corporation Profiles 
        4.9.2   Dendreon Corporation Product Information 
        4.9.3   Dendreon Corporation Urological Cancer Drugs Business Performance  
        4.9.4   Dendreon Corporation Urological Cancer Drugs Business Development and Market Status  
    4.10   Ferring Pharmaceuticals 
        4.10.1   Ferring Pharmaceuticals Profiles 
        4.10.2   Ferring Pharmaceuticals Product Information 
        4.10.3   Ferring Pharmaceuticals Urological Cancer Drugs Business Performance  
        4.10.4   Ferring Pharmaceuticals Urological Cancer Drugs Business Development and Market Status  
    4.11   GlaxoSmithKline 
    4.12   Indevus Pharmaceuticals Inc 
    4.13   Johnson & Johnson 
    4.14   AstraZeneca 
    4.15   Astellas 
5 Market Performance for Manufacturers
    5.1 Global Urological Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    5.2 Global Urological Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    5.3 Global Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
    5.4 Global Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
    5.5 Market Concentration
6 Regions Market Performance for Manufacturers
    6.1 China Market Performance for Manufacturers
        6.1.1 China Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.1.2 China Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.1.3 China Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.1.4 China Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.1.5 Market Concentration
    6.2 USA Market Performance for Manufacturers
        6.2.1 USA Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.2.2 USA Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.2.3 USA Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.2.4 USA Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.2.5 Market Concentration
    6.3 Europe Market Performance for Manufacturers
        6.3.1 Europe Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.3.2 Europe Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.3.3 Europe Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.3.4 Europe Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.3.5 Market Concentration
    6.4 Japan Market Performance for Manufacturers
        6.4.1 Japan Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.4.2 Japan Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.4.3 Japan Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.4.4 Japan Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.4.5 Market Concentration
    6.5 Korea Market Performance for Manufacturers
        6.5.1 Korea Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.5.2 Korea Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.5.3 Korea Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.5.4 Korea Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.5.5 Market Concentration
    6.6 India Market Performance for Manufacturers
        6.6.1 India Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.6.2 India Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.6.3 India Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.6.4 India Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.6.5 Market Concentration
    6.7 Southeast Asia Market Performance for Manufacturers
        6.7.1 Southeast Asia Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.7.2 Southeast Asia Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.7.3 Southeast Asia Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.7.4 Southeast Asia Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.7.5 Market Concentration
    6.8 South America Market Performance for Manufacturers
        6.8.1 South America Urological Cancer Drugs Sales (K Units) and Share of Manufacturers 2013-2018
        6.8.2 South America Urological Cancer Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
        6.8.3 South America Urological Cancer Drugs Price (USD/Unit) of Manufacturers 2013-2018
        6.8.4 South America Urological Cancer Drugs Gross Margin of Manufacturers 2013-2018
        6.8.5 Market Concentration
7 Global  Urological Cancer Drugs Market Performance (Sales Point)
    7.1 Global Urological Cancer Drugs Sales (K Units) and Market Share by Regions 2013-2018
    7.2 Global Urological Cancer Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    7.3 Global Urological Cancer Drugs Price (USD/Unit) by Regions 2013-2018
    7.4 Global Urological Cancer Drugs Gross Margin by Regions 2013-2018
8 Development Trend for Regions (Sales Point)
    8.1 Global Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.2 China Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.3 USA Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.4 Europe Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.5 Japan Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.6 Korea Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.7 India Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.8 Southeast Asia Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    8.8 Southeast Asia Urological Cancer Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
9 Upstream Source, Technology and Cost
    9.1 Upstream Source
    9.2 Technology
    9.3 Cost
10 Channel Analysis
    10.1 Market Channel
    10.2 Distributors
11 Consumer Analysis
    11.1  Prostate Cancer Industry 
    11.2   Bladder Cancer Industry 
    11.3   Kidney Cancer Industry 
12 Market Forecast 2019-2024
    12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
        12.1.1 Global Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
        12.1.2 Global Urological Cancer Drugs Sales (K Units) and Growth Rate 2019-2024
        12.1.3 China Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.4 USA Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.5 Europe Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.6 Japan Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.7 Korea Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.8 India Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.9 Southeast Asia Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.1.10 South America Urological Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
        12.3.1 Overall Market Performance
        12.3.2  Xofigo (Radium Ra 223 Dichloride) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.3.3   Jevtana (Cabazitaxel) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.3.4   Inlyta (Axitinib) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
        12.3.5   Votrient (Pazopanib Hydrochloride) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    12.4 Sales by Application 2019-2024
        12.4.1 Overall Market Performance
        12.4.2  Prostate Cancer Sales and and Growth Rate 2019-2024
        12.4.3   Bladder Cancer Sales and and Growth Rate 2019-2024
        12.4.4   Kidney Cancer Sales and and Growth Rate 2019-2024
        12.4.5   Testicular Cancer Sales and and Growth Rate 2019-2024
    12.5 Price (USD/Unit) and Gross Profit
        12.5.1 Global Urological Cancer Drugs Price (USD/Unit) Trend 2019-2024
        12.5.2 Global Urological Cancer Drugs Gross Profit Trend 2019-2024
13 Conclusion


Inquiry For Buying

Urological Cancer Drugs Sales

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Urological Cancer Drugs Sales

Please fill out the form. We will contact you within 24 hours:
All fields required...
Inquiry For Buying

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you


Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com
-->